Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYE-RES-102 phase 2/3 trial of intravitreal EYE103 versus ranibizumab for diabetic macular edema
MOH_2024-09-29_013665Phase 3Active, not recruiting
- Sponsor
- EyeBio
- Start
- Aug 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of restoret and ranibizumab in diabetic macular edema (DME) (3 arms), sponsored by EyeBio. Primary endpoint: Not specified. Started Aug 2024; status: active, not recruiting.
02
Drugs
restoretranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2024-09-29_013665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-09-29_013665.